Global Immune Checkpoint Inhibitors Market Outlook 2022

  • ID: 4462612
  • Report
  • Region: Global
  • 60 Pages
  • RNCOS E-Services Private Limited
1 of 4
The Global Immune Checkpoint Inhibitors Market is Anticipated to Reach US$ 25 Billion by 2022

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bristol-Myers Squibb
  • CureTech Ltd.
  • EMD Serono, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • MORE

Given the wealth of potential targets to overcome tumor-induced immune suppression, many novel active immunotherapies are in clinical development across a range of solid tumor types. The most advanced in development are checkpoint inhibitors. These checkpoint inhibitors have dramatically altered the natural history of hard-to-treat cancers by producing substantial clinical benefits for certain tumor types and patients. Some of these checkpoints are called PD-1, PD-L1, and CTLA-4 receptors. They work by activating the body's immune system against antigens expressed on tumor cells. Drugs that target these checkpoints hold great promise and have generated a tremendous interest in further developing and exploring these strategies across the oncology disease spectrum.

According to the report “Global Immune Checkpoint Inhibitors Market Outlook 2022”, the global immune checkpoint inhibitors market is anticipated to cross US$ 25 Billion by 2022. The report provides a detailed analysis of the global immune checkpoint inhibitors market. The report also provides the current and forecasted market for immune checkpoint inhibitors. 

Furthermore, the report provides insights about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global immune checkpoint inhibitors market. Moreover, the report provides the sales of commercialized immune checkpoint inhibitors.

The global immune checkpoint inhibitors market has been segmented on the basis of type of product into PD-1, PD-L1, and CTLA-4. According to the report, PD-1 segment was estimated to account for the largest share in 2016 due to entry of multiple pharmaceutical players in the PD-1 inhibitors market, increasing investments from various key pharmaceutical companies and active research with many pharmaceutical companies looking to launch there products.

On the basis of type of cancer, the immune checkpoint inhibitors market is dominated by Lung Cancer & Melanoma applications with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immune checkpoint inhibitors market. 

A major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the report provides information about the immune checkpoint inhibitors programs at various stages of clinical development. In addition, the report highlights the strategic collaborations amongst the players for enhancing their market share.

The latter part of the report discusses some of the prominent players in the global immune checkpoint inhibitors market. A brief business overview of each player has been provided along with their product and pipeline portfolios and recent developments. Overall, immune checkpoint inhibitor is an important and rapidly emerging field. This report will prove as a complete source of knowledge and analysis for clients and potential investors.

READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bristol-Myers Squibb
  • CureTech Ltd.
  • EMD Serono, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • MORE

1. Analyst View

2. Research Methodology

3. Immune Checkpoint Inhibitors: Overview

4. Market Dynamics

    4.1 Drivers

          4.1.1 Increasing Cancer Incidences

          4.1.2 Immune Checkpoint Inhibitors Sales Driving the Market Growth

          4.1.3 Growing Geriatric Population

          4.1.4 High Healthcare Spending in Developed Economies

          4.1.5 Strong Pipeline

          4.1.6 Increasing Efficacy in a Wide Variety of Indications

          4.1.7 Burgeoning Approval and Uptake of Immuno-Oncology Products

    4.2 Challenges

          4.2.1 Increasing Number of Side-Effects Post Immunotherapy Treatments

          4.2.2 Sky-High Development Costs of Cancer Immunotherapies

          4.2.3 High Cost of Treatment

          4.2.4 Lack of Awareness 

    4.3 Opportunities

          4.3.1 Opdivo and Keytruda Presents Significant Growth Opportunity 

          4.3.2 Combination Therapies Could Lead to Substantial Increases in Survival

          4.3.3 Small Companies Offering Huge Opportunites for Next Generation Immunotherapies

5. Global Immune Checkpoint Inhibitors Market Outlook 2022

6. Global Immune Checkpoint Inhibitors Market, by Product Class

    6.1 CTLA-4 Inhibitors (Cytotoxic T-Lymphocyte-Associated Protein-4)

           6.1.1 Yervoy (Ipilimumab)

    6.2 PD-1 and PD-L1 Inhibitors(Programmed Death 1 and Programmed Death Ligand

          6.2.1 Tecentriq (Atezolizumab)

          6.2.2 Bavencio (Avelumab)

          6.2.3 Imfinzi (Durvalumab)

          6.2.4 Opdivo (Nivolumab)

          6.2.5 Keytruda (Pembrolizumab)

7. Application of Immune Checkpoint Inhibitors in Major Indications

    7.1 Head & Neck Cancer

    7.2 Lung Cancer

    7.3 Melanoma

    7.4 Lymphoma

    7.5 Leukemia

    7.6 Others

8. Trends & Developments

    8.1 Lucrative Investment Trend

    8.2 Emergence of Targeted and Combination Therapies

    8.3 NSCLC & Melanoma Showing Greatest Contributions to the IO Market

    8.4 Bristol-Myers Squibb and Merck & Co: Top Immuno-Oncology Dealmakers

9. Strategic Collaborations & Alliances in the Immune Checkpoint Inhibitors Market

10. Pipeline Analysis of Immune Checkpoint Inhibitors

11. Key Players Analysis

      11.1 Genentech, Inc. (A Member of the Roche Group)

      11.2 CureTech Ltd.

      11.3 NewLink Genetics Corporation 

      11.4 Novartis AG

      11.5 Bristol-Myers Squibb

      11.6 Merck & Co., Inc.

      11.7 AstraZeneca Plc

      11.8 Pfizer Inc

      11.9 Ono Pharmaceutical Co., Ltd.

      11.10 EMD Serono, Inc.

List of Tables:

Table 4-1: Immune Checkpoint Inhibitors - Late Stage Research Pipeline

Table 6-1: Ongoing Trials for Yervoy

Table 6-2: Ongoing Trials for Opdivo

Table 6-3: Ongoing Trials for Keytruda

Table 7-1: Global - Oncology Incidence by Geography (‘000), 2015 & 2020

Table 8-1: Selected Immuno-Oncology and Targeted Therapy Combinations

Table 9-1: Strategic Collaborations in the Immune Checkpoint Inhibitors Market

Table 10-1: Active Immune Checkpoint Inhibitors Programs 

Table 10-2: Global - Immune Checkpoint Inhibitors Product Pipeline

Table 11-1: F. Hoffmann-La Roche AG - Key Financials (Billion US$), 2014-2016

Table 11-2: Genentech, Inc. - Commercialized Immune Checkpoint Inhibitors

Table 11-3: Genentech, Inc. – Product Pipeline

Table 11-4: CureTech Ltd. - Product Pipeline

Table 11-5: NewLink Genetics Corporation- Key Financials (Million US$), 2014-2016

Table 11-6: NewLink Genetics Corporation - Product Pipeline

Table 11-7: Novartis AG - Key Financials (Billion US$), 2014-2016

Table 11-8: Novartis AG - Product Pipeline

Table 11-9: Bristol Myers Squibb - Key Financials (Million US$), 2014-2016

Table 11-10: Bristol Myers Squibb - Commercialized Immune Checkpoint Inhibitors

Table 11-11: Bristol Myers Squibb - Product Pipeline

Table 11-12: Merck & Co., Inc. - Key Financials (Million US$), 2014-2016

Table 11-13: Merck & Co., Inc. - Commercialized Immune Checkpoint Inhibitors

Table 11-14: Merck & Co., Inc. - Product Pipeline

Table 11-15: AstraZeneca Plc - Key Financials (Million US$), 2014-2016

Table 11-16: AstraZeneca Plc - Commercialized Immune Checkpoint Inhibitors

Table 11-17: AstraZeneca Plc - Product Pipeline

Table 11-18: Pfizer Inc - Key Financials (Billion US$), 2014-2016

Table 11-19: Pfizer Inc - Commercialized Immune Checkpoint Inhibitors 

Table 11-20: Pfizer Inc - Product Pipeline

Table 11-21: Ono Pharmaceutical Co., Ltd. - Key Financials (Million US$), FY2014-FY2016

Table 11-22: Ono Pharmaceutical Co., Ltd. - Commercialized Immune Checkpoint Inhibitors

Table 11-23: Ono Pharmaceutical Co., Ltd. - Product Pipeline

Table 11-24: EMD Serono, Inc. - Commercialized Immune Checkpoint Inhibitors

Table 11-25: EMD Serono, Inc. - Product Pipeline

List of Figures:

Figure 4-1: Global - Cancer Incidences (Million), 2015, 2020, 2025 & 2030

Figure 4-2: Global - Cancer Mortality (Million), 2015, 2020, 2025 & 2030 

Figure 4-3: Global - Population above 60 Years (Billion), 2015 & 2050

Figure 4-4: Expected Combination Regimen Launches in Oncology

Figure 5-1: Global - Immune Checkpoint Inhibitors Market (Billion US$), 2016-2022

Figure 6-1: Global - Yervoy Market (Million US$), 2012-2018

Figure 6-2: Global - Tecentriq Market (Million US$), 2016 & 2017

Figure 6-3: Global - Bavencio Market (Million US$), 2017-2021

Figure 6-4: Global - Imfinzi Market (Million US$), 2017

Figure 6-5: Global - Opdivo Market (Million US$), 2014-2016

Figure 6-6: Global - Keytruda Market (Million US$), 2014-2016

Figure 7-1: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016

Figure 7-2: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016

Figure 7-3: Lung Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016

Figure 7-4: Lung Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016

Figure 7-5: Melanoma - Immunotherapy Pipeline Analysis by Product (%), 2016

Figure 7-6: Melanoma - Immunotherapy Pipeline Analysis by Phase (%), 2016

Figure 7-7: Lymphoma - Immunotherapy Pipeline Analysis by Product (%), 2016

Figure 7-8: Lymphoma - Immunotherapy Pipeline Analysis by Phase (%), 2016

Figure 7-9: Leukemia - Immunotherapy Pipeline Analysis by Product (%), 2016

Figure 7-10: Leukemia - Immunotherapy Pipeline Analysis by Phase (%), 2016

Figure 7-11: Other Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016

Figure 7-12: Other Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016

Figure 8-1: Immuno-Oncology Funding by Product Type (Billion, US$), 2015-2016

Figure 8-2: Major Investors in Immuno-Oncology Market (2015-2016)

Figure 8-3: Bristol-Myers Squibb and Merck & Co. - Strategic Collaborations

Figure 10-1: Global - Immune Checkpoint Inhibitors Pipeline Analysis by Product Type (%), 2016

Figure 10-2: Global – Immune Checkpoint Inhibitors Pipeline Analysis by Phase (%), 2016

Figure 11-1: F. Hoffmann-La Roche AG - Sales by Business Segments (%), 2016

Figure 11-2: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Segments (%), 2016

Figure 11-3: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Geography (%), 2016

Figure 11-4: Novartis AG - Breakup of Sales by Business Segment (%), 2016

Figure 11-5: Novartis AG - Breakup of Pharmaceuticals Division Sales by Segment (%), 2016

Figure 11-6: Novartis AG - Breakup of Sales by Geography (%), 2016

Figure 11-7: Bristol Myers Squibb - Revenue by Business Segments (%), 2016

Figure 11-8: Bristol Myers Squibb - Revenue by Geography (%), 2016

Figure 11-9: Merck & Co., Inc. - Revenue by Business Segments (%), 2016

Figure 11-10: Merck & Co., Inc. - Pharmaceutical Division Revenue by Segments (%), 2016 

Figure 11-11: Merck & Co., Inc. - Revenue by Geography (%), 2016

Figure 11-12: AstraZeneca Plc - Revenue by Business Segments (%), 2016

Figure 11-13: AstraZeneca Plc - Revenue by Geography (%), 2016

Figure 11-14: Pfizer Inc - Revenue by Business Segments (%), 2016

Figure 11-15: Pfizer Inc - Revenue by Geography (%), 2016

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AstraZeneca Plc
  • Bristol-Myers Squibb
  • CureTech Ltd.
  • EMD Serono, Inc.
  • Genentech, Inc. (A Member of the Roche Group)
  • Merck & Co., Inc.
  • NewLink Genetics Corporation
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll